News
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?
Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...
Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY investors to take profits.
CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, Zepbound, is viewed when compared to Wegovy. That said, despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results